Your browser doesn't support javascript.
loading
Immunogenicity and safety of the third booster dose of the inactivated Japanese encephalitis vaccine in Korean children: A prospective multicenter study.
Kwak, Byung Ok; Kwon, Young Se; Hong, Young Jin; Shin, Seon Hee; Eun, Byung Wook; Ahn, Young Min; Kim, Hwang Min; Kim, Nam Hee; Kim, Dong Hyun.
Afiliação
  • Kwak BO; Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital, Seoul 07441, South Korea.
  • Kwon YS; Department of Pediatrics, Inha University School of Medicine, Incheon 22332, South Korea.
  • Hong YJ; Department of Pediatrics, Inha University School of Medicine, Incheon 22332, South Korea.
  • Shin SH; Department of Pediatrics, Hallym University Dongtan Sacred Heart Hospital, Hwaseong 18450, South Korea.
  • Eun BW; Department of Pediatrics, Eulji Hospital, Eulji University, Seoul 01830, South Korea.
  • Ahn YM; Department of Pediatrics, Eulji Hospital, Eulji University, Seoul 01830, South Korea.
  • Kim HM; Department of Pediatrics, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju 26426, South Korea.
  • Kim NH; Department of Pediatrics, Inje University Ilsan Paik Hospital, Goyang 10380, South Korea.
  • Kim DH; Department of Pediatrics, Inha University School of Medicine, Incheon 22332, South Korea. Electronic address: id@inha.ac.kr.
Vaccine ; 39(14): 1929-1932, 2021 04 01.
Article em En | MEDLINE | ID: mdl-33712352
ABSTRACT
The immunization schedule for the inactivated Japanese encephalitis (JE) vaccine in Korea is a two-dose primary series at 12-24 months of age and three booster doses at 12 months after primary schedule and at 6 and 12 years of age. The aim of this study was to investigate immunogenicity and safety of the third booster dose of the inactivated JE vaccine, as well as the long-term immunogenicity of the second booster dose in Korean children. Healthy children aged 11-13 years, primed and given four doses of inactivated JE vaccines were included. All subjects received the third booster dose of the JE vaccine. Neutralizing antibody (NTAb) titers were assessed before and 4-6 weeks after vaccination using plaque reduction neutralization test (PRNT), and were considered to be protective at ≥ 110. Local and systemic adverse events were monitored for 4 weeks after vaccination. Before and after booster vaccination, all seroprotection rates were 100%. Geometric mean titer (GMT) showed a 6.05-fold increase, from 139.11 (95% CI 110.76, 174.71) to 841.53 (95% CI, 714.25, 991.50). The local tolerability and systemic safety profiles were favorable, with no serious adverse events. In conclusion, the third booster dose of the inactivated JE vaccine was demonstrated to be safe and immunogenic in Korean children when administered according to the current immunization schedule.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encefalite Japonesa / Vacinas contra Encefalite Japonesa Tipo de estudo: Clinical_trials / Observational_studies Limite: Adolescent / Child / Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encefalite Japonesa / Vacinas contra Encefalite Japonesa Tipo de estudo: Clinical_trials / Observational_studies Limite: Adolescent / Child / Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article